3. M. G. Blango and M. A. Mulvey, Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics, Antimicrob. Agents Chemother. 54 (2010) 1855-1863; https://doi.org/10.1128/AAC.00014-1010.1128/AAC.00014-10286363820231390
4. C. Aypak, A. Altunsoy and N. Düzgün, Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: A prospective observational study, Ann. Clin. Microbiol. Antimicrob. 8 (2009) Article ID 27; https://doi.org/10.1186/1476-0711-8-2710.1186/1476-0711-8-27277051519852849
5. J. A. Karlowsky, D. J. Hoban, M. R. Decorby, N. M. Laing and G. G. Zhanel, Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: Results from the North American urinary tract infection collaborative alliance-quinolone resistance study, Antimicrob. Agents Chemother. 50 (2006) 2251-2254; https://doi.org/10.1128/AAC.00123-0610.1128/AAC.00123-06147913216723598
7. T. J. Hannan, I. U. Mysorekar, C. S. Hung, M. L. Isaacson-Schmid and S. J. Hultgren, Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection, PLoS Pathog. 6 (2010) e1001042; https://doi.org/10.1371/journal.ppat.100104210.1371/journal.ppat.1001042293032120811584
8. D. J. Schwartz, S. L. Chen, S. J. Hultgren and P. C. Seed, Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection, Infect. Immun. 79 (2011) 4250-4259; https://doi.org/10.1128/IAI.05339-1110.1128/IAI.05339-11318725621807904
13. H. Connell, W. Agace, P. Klemm, M. Schembri, S. Marild and C. Svanbord, Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract, Proc. Natl. Acad. Sci. USA 93 (1996) 9827-9832.10.1073/pnas.93.18.9827385148790416
15. M. A. Mulvey, Y. S. Lopez-Boado, C. L. Wilson, R. Roth, W. C. Parks, J. Heuser and S. J. Hultgren, Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli, Science 282 (1998) 1494-1497; https://doi.org/10.1126/science.282.5393.149410.1126/science.282.5393.14949822381
16. J. J. Martinez, M. A. Mulvey, J. D. Schilling, J. S. Pinkner and S. J. Hultgren, Type1 pilus-mediated bacterial invasion of bladder epithelial cells, EMBO J. 19 (2000) 2803-2812; https://doi.org/10.1093/emboj/19.12.280310.1093/emboj/19.12.280320335510856226
17. M. Hartmann and T. K. Lindhorst, The bacterial lectin FimH, a target for drug discovery - carbohydrate inhibitors of type 1 fimbriae-mediated bacterial adhesion, Eur. J. Org. Chem. 2011 (2011) 3583-3609; https://doi.org/10.1002/ejoc.20110040710.1002/ejoc.201100407
18. G. G. Anderson, J. J. Palermo, J. D. Schilling, R. Roth, J. Heuser and S. J. Hultgren, Intracellular bacterial biofilm-like pods in urinary tract infections, Science 301 (2003) 105-107; https://doi.org/10.1126/science.108455010.1126/science.108455012843396
19. X. R. Wu, T. T. Sun and J. J. Medina, In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: Relation to urinary tract infections, Proc. Natl. Acad. Sci. USA 93 (1996) 9630-9635.10.1073/pnas.93.18.9630384798790381
20. J. A. Snyder, A. L. Lloyd, C. V. Lockatell, D. E. Johnson and H. L. Mobley, Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection, Infect. Immun. 74 (2006) 1387-1393; https://doi.org/10.1128/IAI.74.2.1387-1393.200610.1128/IAI.74.2.1387-1393.2006136034216428790
22. J. Song, B. L. Bishop, G. Li, R. Grady, A. Stapleton and S. N. Abraham, TLR4-mediated expulsion of bacteria from infected bladder epithelial cells, Proc. Natl. Acad. Sci. USA 106 (2009) 14966-14971; https://doi.org/10.1073/pnas.090052710610.1073/pnas.0900527106
23. P. Thumbikat, R. E. Berry, G. Zhou, B. K. Billips, R. E. Yaggie, T. Zaichuk, T. T. Sun, A. J. Schaeffer and D. J. Klumpp, Bacteria-induced uroplakin signaling mediates bladder response to infection, PLoS Pathog. 5 (2009) e1000415; https://doi.org/10.1371/journal.ppat.100041510.1371/journal.ppat.1000415
24. L. S. Ronald, O. Yakovenko, N. Yazvenko, S. Chattopadhyay, P. Aprikian, W. E. Thomas and E. V. Sokurenko, Adaptive mutations in the signal peptide of the type1fimbrial adhesin of uropathogenic Escherichia coli, Proc. Natl. Acad. Sci. USA 105 (2008) 10937-10942; https://doi.org/10.1073/pnas.080315810510.1073/pnas.0803158105
25. S. L. Chen, C. S. Hung, J. S. Pinkner, J. N. Walker, C. K. Cusumano, Z. Li, J. Bouckaert, J. I. Gordon and S. L. Hultgren. Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding, Proc. Natl. Acad. Sci. USA 106 (2009) 22439-22444; https://doi.org/10.1073/pnas.090217910610.1073/pnas.0902179106
26. D. Choudhury, A. Thompson, V. Stojanoff, S. Langermann, J. Pinkner, S. J. Hultgren and S. D. Knight, X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli, Science 285 (1999) 1061-1066; https://doi.org/10.1126/science.285.5430.106110.1126/science.285.5430.1061
27. C. S. Hung, J. Bouckaert, D. Hung, J. Pinkner, C. Widberg, A. DeFusco, C. G. Auguste, R. Strouse, S. Langermann, G. Waksman and S. J. Hultgren, Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection, Mol. Microbiol. 44 (2002) 903-915; https://doi.org/10.1046/j.1365-2958.2002.02915.x10.1046/j.1365-2958.2002.02915.x
28. J. Bouckaert, J. Berglund, M. Schembri, E. De Genst, L. Cools, M. Wuhrer, C. S. Hung, J. Pinkner, R. Slättegård, A. Zavialov, D. Choudhury, S. Langermann, S. J. Hultgren, L. Wyns, P. Klemm, S. Oscarson, S. D. Knight and H. De Greve, Receptor binding studies disclose a novel class of highaffinity inhibitors of the Escherichia coli FimH adhesin, Mol. Microbiol. 55 (2005) 441-455; https://doi.org/10.1111/j.1365-2958.2004.04415.x10.1111/j.1365-2958.2004.04415.x
29. S. J. Hultgren, F. Lindberg, G. Magnusson, J. Kihlbergt, J. M. Tennent and S. Normark, The PapG adhesin of uropathogenic Escherichia coli contains separate regions for receptor binding and for the incorporation into the pilus, Proc. Nat. Acad. Sci. USA 86 (1989) 4357-4361.10.1073/pnas.86.12.4357
33. J. Bien, O. Sokolova and P. Bozko, Role of uropathogenic Escherichia coli virulence factors in development of urinary tract infection and kidney damage, Int. J. Nephrol. 2012 (2012) Article ID 681473; https://doi.org/10.1155/2012/68147310.1155/2012/681473331227922506110
34. U. Dobrindt, G. Blum-Oehler, T. Hartsch, G. Gottschalk, E. Z. Ron, R. Fünfstück and J. Hacker, S-fimbria-encoding determinant sfa(I) is located on pathogenicity island III(536) of uropathogenic Escherichia coli strain 536, Infect. Immun. 69 (2001) 4248-4256; https://doi.org/10.1128/IAI.69.7.4248-4256.200110.1128/IAI.69.7.4248-4256.20019849411401961
35. T. K. Korhonen, V. Väisänen-Rhen, M. Rhen, A. Pere, J. Parkkinen and J. Finne, Escherichia coli fimbriae recognizing sialyl galactosides, J. Bacteriol. 159 (1984) 762-766.10.1128/jb.159.2.762-766.19842157116146600
36. A. S. Khan, I. Mühldorfer, V. Demuth, U. Wallner, T. K. Korhonen and J. Hacker, Functional analysis of the minor subunits of S fimbrial adhesion (SfaI) in pathogenic Escherichia coli, Mol. Gen. Genet. 263 (2000) 96-105; https://doi.org/10.1007/PL0000868010.1007/PL0000868010732678
37. M. Castelain, S. Ehlers, J. Klinth, S. Lindberg, M. Andersson, B. E. Uhlin and O. Axner, Fast uncoiling kinetics of F1C pili expressed by uropathogenic Escherichia coli are revealed on a single pilus level using force-measuring optical tweezers, Eur. Biophys. J. 40 ( 2011) 3 05-316; https://doi.org/10.1007/s00249-010-0648-110.1007/s00249-010-0648-121161524
38. F. Backhed, B. Alsen, N. Roche, J. Angstrom, A. von Euler, M. E. Breimer, B. Westerlund-Wikstrom, S. Teneberg and A. Richter-Dahlfors, Identification of target tissue glycosphingolipid receptors for uropathogenic, F1C-fimbriated Escherichia coli and its role in mucosal inflammation, J. Biol. Chem. 227 (2002) 18198-18205; https://doi.org/10.1074/jbc.M11164020010.1074/jbc.M11164020011877427
40. N. Riegman, H. Hoschützky, I. van Die, W. Hoekstra, K. Jann and H. Bergmans, Immunocytochemical analysis of P-fimbrial structure: localization of minor subunits and the influence of the minor subunit FsoE on the biogenesis of the adhesin, Mol. Microbiol. 4 (1990) 1193-1198; https://doi.org/10.1111/j.1365-2958.1990.tb00694.x10.1111/j.1365-2958.1990.tb00694.x1978223
42. T. K. Lindhorst, C. Kieburg and U. Krallmann-Wenzel, Inhibition of the type 1 fimbriae-mediated adhesion of Escherichia coli to erythrocytes by multiantennary alpha-mannosyl clusters: the effect of multivalency, Glycoconjugate J. 15 (1998) 605-613; https://doi.org/10.1023/A:100692002764110.1023/A:1006920027641
43. T. K. Lindhorst, S. Kötter, U. Krallmann-Wenzel and S. Ehlers, Trivalent α-d-mannoside clusters as inhibitors of type-1 fimbriae-mediated adhesion of Escherichia coli: structural variation and biotinylation, J. Chem. Soc. Perkin Trans. 1 8 (2001) 823-831; https://doi.org/10.1039/B009786L10.1039/b009786l
44. C. Heidecke and T. K. Lindhorst, Iterative synthesis of spacered glycodendrons as oligomannoside mimetics and evaluation of their antiadhesive properties, Chem. Eur. J. 13 (2007) 9056-9067; https://doi.org/10.1002/chem.20070078710.1002/chem.200700787
45. M. Touaibia, A. Wellens, T. C. Shiao, Q. Wang, S. Sirois, J. Bouckaert and R. Roy, Mannosylated G(0) dendrimers with nanomolar affinities to Escherichia coli FimH, ChemMedChem 2 (2007) 1190-1201; https://doi.org/10.1002/cmdc.20070006310.1002/cmdc.200700063
46. O. Schwardt, S. Rabbani, M. Hartmann, D. Abgottspon, M. Wittwer, S. Kleeb, A. Zalewski, M. Smieško, B. Cutting and B. Ernst, Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists, Bioorg. Med. Chem. 19 (2011) 6454-6473; https://doi.org/10.1016/j.bmc.2011.08.05710.1016/j.bmc.2011.08.057
47. N. Nagahori, R. T. Lee, S. I. Nishimura, D. Pagé, R. Roy and Y. C. Lee, Inhibition of adhesion of type 1 fimbriated Escherichia coli to highly mannosylated ligands, ChemBioChem 3 (2002) 836-844; https://doi.org/10.1002/1439-7633(20020902)3:9<;836::AID-CBIC836>3.0.CO;2-210.1002/1439-7633(20020902)3:9<;836::AID-CBIC836>3.0.CO;2-2
48. M. Dubber, O. Sperling and T. K. Lindhorst, Oligomannoside mimetics by glycosylation of ‘octopus glycosides’ and their investigation as inhibitors of type 1 fimbriae-mediated adhesion of Escherichia coli, Org. Biomol. Chem. 4 (2006) 3901-3912; https://doi.org/10.1039/B610741A10.1039/B610741A
49. Z. Han, J. S. Pinkner, B. Ford, R. Obermann, W. Nolan S. A Wildman, D. Hobbs, T. Ellenberger, K. Cusumano, S. J. Hultgren and J. W. Janetka, Structure-based drug design and optimization of mannoside bacterial FimH antagonists, J. Med. Chem. 53 (2010) 4779-4792; https://doi.org/10.1021/jm100438s10.1021/jm100438s
50. A. Wellens, C. Garofalo, H. Nguyen, N. VanGerven, R. Slättegård, J. P. Hernalsteens, L. Wyns, S. Oscarson, H. DeGreve, S. Hultgren and J. Bouckaert, Intervening with urinary tract infections using anti-adhesives based on the crystal structure of theFimH-oligomannose-3 complex, PLoS One 3 (2008) e2040; https://doi.org/10.1371/journal.pone.000204010.1371/journal.pone.0002040
51. R. Ribić, M. Kovačević, V. Petrović-Peroković, I. Gruić-Sovulj, V. Rapić and S. Tomić, Synthesis and biological activity of mannose conjugates with 1-adamantamine and ferrocene amines, Croat. Chem. Acta 83 (2010) 421-431.
52. M. Kovačević, L. Barišić, R. Ribić, V. Petrović Peroković, S. Tomić and V. Rapić, Ferrocene conjugates with mannose: synthesis and influence of ferrocene aglycon on mannose-mediated adhesion of Escherichia coli, Appl. Organometal. Chem. 26 (2012) 74-79; https://doi.org/10.1002/aoc.186910.1002/aoc.1869
53. V. Kovač, R. Ribić, V. Petrović Peroković, S. Tomić and L. Barišić, Synthesis, spectral characterization and inhibitory potency of ferrocene-containing mannosides towards type 1 fimbriated Escherichia coli, Appl. Organometal. Chem. 30 (2013) 524-530; https://doi.org/10.1002/aoc.346510.1002/aoc.3465
54. T. K. Lindhorst, S. Kötter, J. Kubisch, U. Krallmann-Wenzel, S. Ehlers and V. Křen, Effect of psubstitution of aryl α-d-mannosides on inhibiting mannose-sensitive adhesion of Escherichia coli - syntheses and testing, Eur. J. Org. Chem. 1998 (1998) 1669-1674; https://doi.org/10.1002/(SICI)1099-0690(199808)1998:8<;1669::AID-EJOC1669>3.0.CO;2-Q10.1002/(SICI)1099-0690(199808)1998:8<;1669::AID-EJOC1669>3.0.CO;2-Q
55. N. Firon, S. Ashkenazi, D. Mirelman, I. Ofek and N. Sharon, Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast a find intestinal epithelial cells, Infect. Immun. 55 (1987) 472-476.10.1128/iai.55.2.472-476.1987
56. O. Sperling, A. Fucha and T. K. Lindhorst, Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: design, synthesis and binding properties of mannoside ligands, Org. Biomol. Chem. 4 (2006) 3913-3922; https://doi.org/10.1039/b610745a10.1039/b610745a
57. Ž. Car, T. Hrenar, V. Petrović Peroković, R. Ribić, M. Seničar and S. Tomić, Mannosylated N-aryl substituted 3-hydroxypyridine-4-ones: synthesis, hemagglutination inhibitory properties, and molecular modeling, Chem. Biol. Drug Des. 84 (2014) 393-401; https://doi.org/10.1111/cbdd.1232910.1111/cbdd.12329
58. V. Petrović Peroković, R. Ribić, Ž. Car and S. Tomić, Comparison of inhibitory activities of meta and para substituted N-aryl 3-hydroxypyridin-4-one mannosides towards type 1 fimbriated E. coli, Croat. Chem. Acta 89 (2016) 237-242; https://doi.org/10.5562/cca289010.5562/cca2890
60. S. Kleeb, L. Pang, K. Mayer, D. Eris, A. Sigl, R. C. Preston, P. Zihlmann, T. Sharpe, R. P. Jakob, D. Abgottspon, A. S. Hutter, M. Scharenberg, X. Jiang, G. Navarra, S. Rabbani, M. Smiesko, N. Lüdin, J. Bezençon, O. Schwardt, T. Maier and B. Ernst, FimH antagonists: Bioisosteres to improve the in vitro and in vivo PK/PD profile, J. Med. Chem. 58 (2015) 2221-2239; https://doi.org/10.1021/jm501524q10.1021/jm501524q
61. K. L. LaPlante, S. A. Sarkisian, S. Woodmansee, D. C. Rowley and N. P. Seeram, Effects of cranberry extracts on growth and biofilm production of Escherichia coli and Staphylococcus species, Phytother. Res. 26 (2012) 1371-1374; https://doi.org/10.1002/ptr.459210.1002/ptr.4592
62. A. Gupta, M. Dwivedi, A. A. Mahdi, G. A. Nagana Gowda, C. L. Khetrapal and M. Bhandari, Inhibition of adherence of multi-drug resistant E. coli by proanthocyanidin, Urol. Res. 40 (2012) 143-150; https://doi.org/10.1007/s00240-011-0398-210.1007/s00240-011-0398-221688109
64. J. Sun, J. P. J. Marais, C. Khoo, K. LaPlante, R. M. Vejborg, M. Givskov, T. Tolker-Nielsen, N. P. Seeram and D. C. Rowley, Cranberry (Vaccinium macrocarpon) oligosaccharides decrease biofilm formation by uropathogenic Escherichia coli, J. Funct. Foods 17 (2015) 235-242; https://doi.org/10.1016/j.jff.2015.05.01610.1016/j.jff.2015.05.016465787326613004
65. E. Papas and K. M. Schaich, Phytochemicals of cranberries and cranberry products: Characterization, potential health effects and processing stability, Crit. Rev. Food Sci. Nutr. 49 (2009) 741-781; https://doi.org/10.1080/1040839080214537710.1080/1040839080214537720443158
66. D. G. de Llano, A. Esteban-Fernández, F. Sánchez-Patán, P. J. Martínlvarez, M. V. Moreno-Arribas and B. Bartolomé, Anti-adhesive activity of cranberry phenolic compounds and their microbialderived metabolites against uropathogenic Escherichia coli in bladder epithelial cell cultures, Int. J. Mol. Sci. 16 (2015) 12119-12130; https://doi.org/10.3390/ijms16061211910.3390/ijms160612119449043326023719
67. R. P. Felician, C. G. Krueger and J. D. Reed, Methods to determine effects of cranberry proanthocyanidins on extraintestinal infections: Relevance for urinary tract health, Mol. Nutr. Food Res. 59 (2015) 1292-1306; https://doi.org/10.1002/mnfr.20150010810.1002/mnfr.20150010825917127
68. R. Rajbhandari, N. Peng, R. Moore, A. Arabshahi, J. M. Wyss, S. Barnes and J. K. Prasain, Determination of cranberry phenolic metabolites in rats by liquid chromatography-tandem mass spectrometry, J. Agric. Food Chem. 59 (2011) 6682-6688; https://doi.org/10.1021/jf200673h10.1021/jf200673h316505021634376
69. A. B. Howell, H. Botto, C. Combescure, A.-B. Blanc-Potard, L. Gausa, T. Matsumoto, P. Tenke, A. Sotto and J.-P. Lavigne, Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study, BMC Infect. Dis. 10 (2010) Article ID 94; https://doi.org/10.1186/1471-2334-10-9410.1186/1471-2334-10-94287355620398248
70. L. Y. Foo, Y. Lu, A. B. Howell and N. Vorsa, A-type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli, J. Nat. Prod. 63 (2000) 1225-1228; https://doi.org/10.1021/np000128u10.1021/np000128u11000024
72. K. Valentova, D. Stejskal, P. Bednar, J. Vostalova, C. Cíhalík, R. Vecerova, D. Koukalova, M. Kolar, R. Reichenbach. L. Sknouril, J. Ulrichova and V. Simanek, Biosafety, antioxidant status, and metabolites in urine after consumption of dried cranberry juice in healthy women: a pilot doubleblind placebo-controlled trial, J. Agric. Food Chem. 55 (2007) 3217-3224; https://doi.org/10.1021/jf063601410.1021/jf063601417381122
74. M. A. Polewski, C. G. Krueger, J. D. Reed and G. Leyer, Ability of cranberry proanthocyanidins in combination with a probiotic formulation to inhibit in vitro invasion of gut epithelial cells by extra-intestinal pathogenic E. coli, J. Funct. Foods 25 (2016) 123-134; https://doi.org/10.1016/j.jff.2016.05.01510.1016/j.jff.2016.05.015
75. D. Nicolosi, G. Tempera, C. Genovese and P. M. Furneri, Anti-adhesion activity of A2-type proanthocyanidins (a cranberry major component) on uropathogenic E. coli and P. mirabilis strains, Antibiotics (Basel) 3 (2014) 143-154; https://doi.org/10.3390/antibiotics302014310.3390/antibiotics3020143479039427025740
76. M. A. Amalaradjou, A. Narayanan and K. Venkitanarayanan, Trans-cinnamaldehyde decreases attachment and invasion of uropathogenic Escherichia coli in urinary tract epithelial cells by modulating virulence gene expression, J. Urol. 185 (2011) 1526-1531; https://doi.org/10.1016/j.juro.2010.11.07810.1016/j.juro.2010.11.07821334666
77. A. E. Stapleton, J. Dziura, T. M. Hooton, M. E. Cox, Y. Yarova-Yarovaya, S. Chen and K. Gupta, Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial, Mayo Clin. Proc. 87 (2012) 143-150; https://doi.org/10.1016/j.mayocp.2011.10.00610.1016/j.mayocp.2011.10.006349755022305026
78. Â. Luís, F. Domingues and L. Pereira, Can cranberries contribute to reduce the incidence of urinary tract infections? - A systematic review with meta-analysis and trial sequential analysis of clinical trials, J. Urol. 198 (2017) 614-621; https://doi.org/10.1016/j.juro.2017.03.07810.1016/j.juro.2017.03.07828288837
79. R. Fumeaux, C. Menozzi-Smarrito, A. Stalmach, C. Munari, K. Kraehenbuehl, H. Steiling, A. Crozier, G. Williamson and D. Barron, First synthesis, characterization, and evidence for the presence of hydroxycinnamic acid sulfate and glucuronide conjugates in human biological fluids as a result of coffee consumption, Org. Biomol. Chem. 8 (2010) 5199-5211; https://doi.org/10.1039/c0ob00137f10.1039/c0ob00137f20842300
80. C. G. Krueger, J. D. Reed, R. P. Feliciano and A. B. Howell, Quantifying and characterizing proanthocyanidins in cranberries in relation to urinary tract health, Anal. Bioanal. Chem. 405 (2013) 4385-4395; https://doi.org/10.1007/s00216-013-6750-310.1007/s00216-013-6750-323397091